Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Previous Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Solutions for Trial Design Challenges in Rare Disease Trials Accelerating Rare Disease Therapies: Strategies for Efficient Clinical Development Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Beyond the Feasibility Survey: Strategic Site Selection to Accelerate Trials and Optimize Resources Ethics and Strategies for Returning Individual Patient Data Collected in Clinical Research
Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Previous Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Solutions for Trial Design Challenges in Rare Disease Trials Accelerating Rare Disease Therapies: Strategies for Efficient Clinical Development Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Beyond the Feasibility Survey: Strategic Site Selection to Accelerate Trials and Optimize Resources Ethics and Strategies for Returning Individual Patient Data Collected in Clinical Research
